#USA #New York #Class Action #Levi & Korsinsky #Revance Therapeutics

Class Action Alert for Revance Therapeutics, Inc.

Investors in Revance Therapeutics, Inc. (NASDAQ: RVNC), a biopharmaceutical company, are being urged to join a class action lawsuit following substantial financial losses attributed to alleged securities fraud. The firm Levi & Korsinsky, LLP has stepped in to notify these shareholders of their rights and potential compensation.

Background of the Case

The class action lawsuit is specifically addressing losses incurred by shareholders between February 29, 2024, and December 6, 2024. The complaint alleges that Revance made false and misleading statements, which concealed various breaches related to a Distribution Agreement with Teoxane. The agreement allowed Revance exclusive rights to import and market Teoxane's line of dermal fillers.

The allegations highlight significant breaches that posed increased risks of litigation and financial repercussions for Revance. Furthermore, these inadequacies are believed to have affected the bona fides of the company's public statements during that period.

The ramifications of these distortions are severe. Shareholders are likely facing a compounded impact of monetary and reputational harm, culminating from Revance’s failure to disclose crucial information that influenced their stock's value.

What Should Affected Shareholders Do?

Shareholders who believe they have suffered losses are encouraged to act quickly. They have until March 4, 2025, to submit their case to the Court and request appointment as lead plaintiff. However, it's crucial to note that simply participating in this class action does not require being a lead plaintiff to share in any compensation awarded.

Notably, all participants in the class action will not incur any out-of-pocket costs or fees, ensuring a risk-free opportunity to partake in potential recovery efforts.

Why Choose Levi & Korsinsky?

Levi & Korsinsky stands out for its extensive experience in securities litigation, having recovered hundreds of millions of dollars for aggrieved shareholders over the past two decades. With a robust team of over 70 professionals dedicated to their clients' claims, they are well-prepared to navigate complex legal landscapes. For seven consecutive years, their firm has been recognized among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

Next Steps for Potential Plaintiffs

If you are an investor in Revance Therapeutics who faced losses during the designated period, contact Levi & Korsinsky immediately. You can reach out to Attorney Joseph E. Levi directly at (212) 363-7500 or via email at [email protected].

Act now to ensure you take the necessary steps to protect your rights. The opportunity for compensation awaits time-sensitive action, urging prompt participation in this lawsuit.

Contact Information

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500
Website: www.zlk.com

Don't miss this vital opportunity to regain what you've lost and hold Revance accountable for their actions that have impacted you and other investors alike.